Industry News Archive

Registration Open: Review of Efficacy and Safety of Monjuvi® (tafasitamab-cxix)

incyte-logoMonjuvi® (tafasitamab-cxix, Incyte) in combination with lenalidomide, is indicated for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) not otherwise specified, including DLBCL arising from low grade lymphoma, and who are not eligible for autologous stem cell transplant (ASCT).

This indication is approved under accelerated approval based on overall response rate. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).

Join a one-hour webcast, Review of Efficacy and Safety of Monjuvi (tafasitamab-cxix): FDA-approved monoclonal antibody in combination with lenalidomide for adult patients with R/R DLBCL who have received at least one prior therapy, to learn more about the usage of Monjuvi®, (tafasitamab-cxix) in treating your patients. 

Wednesday, December 16
1:00 - 2:00 PM EST

Presented by:
Moshe Levy, MD
Director of Hematologic Malignancies Research; Hematology Associate
Texas Oncology, PA; Baylor University College of Medicine


Wednesday, December 16
3:00 - 4:00 PM EST

Presented by:
John M. Pagel, MD, PhD
Chief of Hematologic Malignancies and Director of Stem Cell Transplantation
Swedish Cancer Institute


1801 Research Boulevard Suite 400
Rockville, MD 20850
Tel: 301.984.9496 | Fax: 301.770.1949
Email Us